Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma

by rob@robmaguiredesigns.com | Aug 19, 2025 | Press Releases

KLN-1010 is the first anti-BCMA in vivo CAR-T program studied in a multi-center clinical trial KLN-1010 is administered directly to patients without apheresis, ex vivo manufacturing or lymphodepletion BOSTON–Kelonia Therapeutics, Inc., a biotech company...

Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting

by rob@robmaguiredesigns.com | May 9, 2025 | Press Releases

BOSTON, Mass., May 9, 2025 – Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced new preclinical data of its in vivo Gene Placement System (iGPS®) will be highlighted at the...

PharmaPhorum: Viva in vivo – The next generation of cell therapy is fast approaching

by rob@robmaguiredesigns.com | Oct 28, 2024 | News

Kelonia Therapeutics to Participate in Upcoming Scientific Conferences

by rob@robmaguiredesigns.com | May 2, 2024 | Press Releases

BOSTON, Mass., May 2, 2024 – Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two...

Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma

by rob@robmaguiredesigns.com | Apr 2, 2024 | Press Releases

– Preclinical data supports potential for iGPS® particles to provide off-the-shelf in vivo CAR-T Cell therapies without need for lymphodepleting chemotherapy – BOSTON, Mass., April 2, 2024 – Kelonia Therapeutics, a biotech company revolutionizing in vivo gene...